Guard Medical Reports an $11 Million Series B Investment for Its Novel NPsealTM, the First All-in-One NPWT Surgical Dressing

Privately-held company Guard Medical Inc. today announces the completion of a Series B investment of $11 million to support commercialization and clinical studies of its next generation Negative Pressure Wound Therapy (NPWT) dressing NPseal^TM for the treatment of closed surgical incisions. NPseal^TM is an easy-to-use and cost-effective NPWT surgical dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.

“The completion of the Series B demonstrates the confidence of the investors to support the next phase of our NPseal^TM. Securing additional funding will enable new clinical studies, increased commercialization and leveraging the NPseal^TM technology into the high exuding and chronic wounds segments,” stated Machiel van der Leest, CEO of Guard Medical. “The now confirmed NPseal^TM ease-of-use and cost effectiveness makes, for the first time, prophylactic use of NPWT for all eligible closed surgical incisions possible.”

NPWT has been shown to reduce Surgical Site Infections (SSI) in a large number of peer reviewed articles but is in limited use due to its high cost and complexity. While being easy-to-use, NPseal^TM delivers the same NPWT as the more expensive and complex NPWT competitive devices.

Guard Medical Inc. (www.guard-medical.com), a privately-held company, is developing easy-to-use and cost-effective solutions that enables prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physician’s identification of unmet needs related to Surgical Site Infections (SSI). Current investors include Bpifrance and Matignon Investissement et Gestion.

Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005054/en/